您好，欢迎光临世界标品！ 登录 注册（订药物标准品请用邮件联系我们）

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索（中英文）：
世界各国官方药品目录搜索（英文）：
世界标品医药知识搜索（中英文）：

美国药房|加拿大药房|英国药房|瑞士药房|澳大利亚药房|新西兰药房|香港药房|印度药房|新加坡药房|俄罗斯药房|法律的依据
日本药房|德国药房|孟加拉药房|巴西药房|欧洲共同体药房|土耳其药房|以色列药房|法国药房|罗马尼亚药房|墨西哥药房|爱尔兰药房
荷兰药房|意大利药房|保加利亚药房|南非药房|芬兰药房|挪威药房
联系方式
国内客服电话：
国际免费电话：

咨询邮箱：
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 英国药房
产地国家: 英国
所属类别: 糖尿病->2型糖尿病
处方药:处方药
包装规格: 12.5毫克/850毫克 28片/盒
计价单位:
   
生产厂家中文参考译名:
武田
生产厂家英文名:
 Takeda
该药品相关信息网址1:
 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002654/human_med_001695.jsp&mid=WC0b01ac058001d124
该药品相关信息网址2:
 http://www.medicines.org.uk/emc/medicine/28512
 原产地英文商品名:
 Vipdomet12.5mg/850mg 28 tablets (Minimum order qty: 3)
原产地英文药品名:
 Alogliptin/Metformin HCL
中文参考商品译名:
 Vipdomet 12.5毫克/850毫克 28片/盒 ) (最低订货量：3)
中文参考药品译名:
 阿格列汀/二甲双胍复方片
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
 Type 2 Diabetes
 临床试验期:
 完成
中文适应病症参考翻译1:
 2型糖尿病
药品信息:
二肽基肽酶IV(DPP-4)抑制剂Vipdomet(alogliptin/ metformin) 商品名：Vipdomet 规格：12.5mg/850mg 厂家：Takeda Pharma A/S 上市时间：原研：武田，欧盟/美国2013年批准 Takeda Pharma AG 武田3种糖尿病新药获欧盟批准 武田（Takeda）9月24日宣布，3种2型糖尿病新药：二肽基肽酶IV（DPP-4）抑制剂Vipidia（alogliptin）、固定剂量组合Vipdomet（alogliptin+二甲双胍）、Incresync（alogliptin+吡格列酮）均获得了欧盟委员会（EC）批准，用于现有疗法无法控制其血糖水平的2型糖尿病患者。 这3种新药的获批，是基于一项强有力的临床试验项目的数据。该项目涉及超过11000名患者，治疗时间长达4年，以及2项关键性研究的数据、ENDURE研究的一年数据及EXAMINE实验的中期数据。 该项目，将alogliptin作为饮食和运动的辅助（adjunct）疗法、以及将alogliptin作为其他几类降糖药物（如二甲双胍、吡格列酮、胰岛素、磺脲类药物）的附加（add-on）疗法进行了疗效研究。 这些研究中，每日一次25mg剂量alogliptin表现出了临床和统计学意义的HbA1c水平降低，同时表现出良好的整体耐受性和低血糖发生率。 此外，研究表明，与二甲双胍或吡格列酮单药治疗相比，alogliptin与二甲双胍或吡格列酮联合用药能够显着地改善血糖水平的控制。固定剂量组合药物Vipdomet（alogliptin-二甲双胍）和Incresync（alogliptin-吡格列酮）提供了额外的好处，可能有助于患者减少每日必须服用的药丸数量。 Alogliptin是一种选择性二肽基肽酶IV（DPP-4）抑制剂，该药于2010年4月获得日本卫生劳动福利部（MHLW）批准，目前以商品名Nesina销售。固定剂量组合（alogliptin-pioglitazone）于2011年在日本获批，以商品名Liovel销售。 2型糖尿病是糖尿病中最常见的形式，已达到了全球流行病规模（epidemic size）。据粗略估计，全球约有3.36亿成年人患有2型糖尿病。到2030年，预计每9个成年人中就有1位2型糖尿病患者。在2010年，用于糖尿病及其并发症的国际医疗费用达3760亿美元，预计到2030年，这一数字将超过4900亿美元。 Dipeptidyl peptidase IV (DPP-4) inhibitor Vipdomet (alogliptin / metformin) Product name: Vipdomet Specifications: 12.5mg / 850mg Manufacturers: Takeda Pharma A / S Time to market: the original research: Takeda, EU / U.S. in 2013 approved Takeda Pharma AG Takeda three kinds of diabetes drug won EU approval Takeda (Takeda) 9 月 24 announced, three kinds of type 2 diabetes drug: dipeptidyl peptidase IV (DPP-4) inhibitor Vipidia (alogliptin), a fixed-dose combination Vipdomet (alogliptin + metformin), Incresync (alogliptin + pioglitazone) are won the European Commission (EC) approved for existing therapies can not control their blood sugar levels in type 2 diabetes. These three kinds of new drugs approved, is based on data from a robust clinical trial program. The project involved more than 11,000 patients, treatment for up to four years, as well as data two pivotal studies, the mid-year data and data EXAMINE experiment ENDURE study. The project will alogliptin as an adjunct to diet and exercise (adjunct) therapy, as well as several other categories will alogliptin antidiabetic drugs (such as metformin, pioglitazone, insulin, sulfonylureas) additional (add-on) therapy were efficacy the study. These studies, once-daily dose of 25mg alogliptin showed clinically and statistically significant lower HbA1c levels, while showing a good overall tolerability and incidence of hypoglycemia. In addition, studies show that compared with metformin or pioglitazone monotherapy, alogliptin with metformin or pioglitazone combination therapy can significantly improve the control of blood glucose levels. Fixed-dose combination drug Vipdomet (alogliptin- metformin) and Incresync (alogliptin- pioglitazone) provides additional benefits, may help reduce the number of pills patients must be taken daily. Alogliptin is a selective dipeptidyl peptidase IV (DPP-4) inhibitor drug in April 2010 to get the Japanese Ministry of Health Labor and Welfare (MHLW) approval, currently sold under the trade name Nesina. Fixed-dose combinations (alogliptin-pioglitazone) approved in Japan in 2011, under the trade name Liovel sales. Type 2 diabetes is the most common form of diabetes has reached epidemic worldwide scale (epidemic size). According to rough estimates, there are around 336 million adults suffer from type 2 diabetes. By 2030, every nine adults are expected to have a type 2 diabetic patients. In 2010, the international medical costs for diabetes and its complications reached $ 376 billion, projected to 2030, this figure will be more than 490 billion U.S. dollars.
更新日期: 2014-10-22
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间：太平洋时间18:00-24:00
国内客服电话：     国际免费电话：
友情提示：以上电话为免费电话，无需您承担任何费用，世界标品提供中文客服，请您放心拨打！
电子邮箱：sciteck.hongkong@gmail.com, 15901965168@163.com